|1.||Atadja, Peter: 36 articles (01/2015 - 02/2005)|
|2.||Fiskus, Warren: 13 articles (05/2014 - 02/2005)|
|3.||Richardson, Paul G: 10 articles (01/2016 - 11/2011)|
|4.||Ocker, Matthias: 9 articles (01/2016 - 01/2010)|
|5.||Bhalla, Kapil N: 9 articles (05/2014 - 04/2009)|
|6.||Johnstone, Ricky W: 8 articles (11/2015 - 07/2008)|
|7.||Prince, H Miles: 8 articles (05/2014 - 07/2008)|
|8.||Rao, Rekha: 8 articles (04/2012 - 12/2006)|
|9.||San-Miguel, Jesús F: 7 articles (01/2016 - 05/2010)|
|10.||Sharma, Sunil: 7 articles (01/2015 - 08/2006)|
01/01/2015 - "Moreover, some of the mice treated with the panobinostat/ATO combination showed complete tumor responses and remained in remission for over 220 days. "
07/01/2012 - "Intravenous administration of LBH589 in immunodeficient BALB/c-RAG2(-/-)γc(-/-) mice in which human-derived T and B-ALL cell lines were injected induced a significant reduction in tumor growth. "
01/01/2010 - "Panobinostat is a well tolerated new treatment option for HCC that activates alternative pathways of apoptosis, also in p53-deficient tumors."
07/01/2012 - "In CEA/Tag mice, LBH589 induced tumor-cell expression of CITED2 and increased the efficacy of anthracycline to reduce tumor growth. "
11/01/2010 - "Moreover, cancer cell sensitivity to panobinostat treatment may be further improved by combination with inhibition of anti-apoptotic factors. "
01/01/2010 - "LBH589 may be very effective in multiple myeloma after a multitude of preceding treatments that could not induce a long-term anti-myeloma effect. "
12/01/2014 - "In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease. "
02/01/2015 - "Panobinostat: a review of trial results and future prospects in multiple myeloma."
09/01/2012 - "Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma."
01/01/2016 - "Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes."
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2013 - "This study provides pre-clinical evidence that HDAC6 may serve as a sensitive therapeutic target in the treatment of prostate cancer with HDACI LBH589 for clinical translation. "
04/01/2013 - "LBH589 dose-dependently blocked prostate cancer cell growth. "
01/01/2013 - "The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation."
01/15/2011 - "Taken together, our data suggest that HNE potentiates the antitumoral effect of the HDACI panobinostat in prostate cancer cells."
09/01/2013 - "A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer."
|4.||Glioblastoma (Glioblastoma Multiforme)
06/01/2015 - "Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma."
01/28/2015 - "This study was conducted to compare the efficacy of SAHA, LBH589, Valproic Acid (VPA), MS275 and Scriptaid in the patient-derived glioblastoma model. "
11/01/2014 - "We study the efficacy of SAHA/RTx and LBH589/RTx when manipulating Bcl-2 family proteins using the Bcl-2 inhibitor Obatoclax in patient-derived glioblastoma stem-like cell (GSC) cultures. "
01/28/2015 - "DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells."
11/01/2014 - "The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells."
|5.||Breast Neoplasms (Breast Cancer)
06/01/2014 - "A panel of breast cancer cell lines (MCF-7, MDA-MB-231, and BT-549), drugged with LBH589, was examined for changes in cell morphology, migration, and invasion in vitro. "
03/01/2014 - "Taking into consideration its anti-proliferative and anti-invasive properties, we suggest the use of LBH589 in aggressive breast cancer refractory to hormonal therapy. "
01/01/2013 - "In all, our findings strongly support further investigation of LBH589 as a novel therapeutic strategy for patients with AI-resistant breast cancer, in part by suppressing the NF-κB1 pathway."
01/01/2012 - "Our results demonstrate a potential therapeutic role of panobinostat in targeting aggressive triple-negative breast cancer cell types."
01/01/2012 - "Simultaneous treatment of breast cancer cell lines with LBH589 and 5azaC did not show significant synergy in killing cells. "
|1.||Histone Deacetylase Inhibitors
|4.||vorinostat (suberoylanilide hydroxamic acid)
|7.||Histone Deacetylases (Histone Deacetylase)
|8.||sorafenib (BAY 43-9006)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|5.||Stem Cell Transplantation